Asia Tech Wire (Oct 25) -- Novo Nordisk's weight-loss drug Ozempic may help lower the risk of Alzheimer's disease, a study released Thursday found.

Researchers at Case Western Reserve University School of Medicine, including Rong Xu, William Wang and Mark Gurney, studied three years worth of electronic health records of nearly 1 million people with type 2 diabetes.

The latest analysis of these electronic records shows that Ozempic may help reduce the risk of developing Alzheimer's disease,

The study found that Ozempic, along with other GLP-1 therapies, may delay or prevent the memory-robbing condition in diabetes patients.

Semaglutide, the active ingredient in Ozempic, was associated with a 40-70% reduction in the risk of a first-time Alzheimer's diagnosis in diabetes patients compared to seven other antidiabetic medications.